Caricamento...
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
RET receptor tyrosine kinase (RTK) acts as an ontogenetic driver in several human malignancies, including papillary and medullary thyroid carcinoma, lung adenocarcinoma, colorectal carcinoma, Spitzoid neoplasms, salivary gland carcinoma and chronic myeloproliferative disorders, secondary to as diver...
Salvato in:
| Pubblicato in: | Best Pract Res Clin Endocrinol Metab |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5624797/ https://ncbi.nlm.nih.gov/pubmed/28911727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beem.2017.04.013 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|